Colorado Clinical Trials Report — June 2026

For Coloradans considering participation in clinical research, June 2026 presents a critical window of opportunity, particularly for trials nearing their conclusion. Across the state, 103 clinical trials are slated to close within the next 90 days, meaning time is running out to enroll. This urgent call includes 15 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various cancers, metabolic conditions, and neurological disorders are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (3 trials)
• Triple negative breast cancer (2 trials)
• B-cell acute lymphoblastic leukemia (2 trials)
• Head and neck squamous cell carcinoma (2 trials)
• Smoking cessation (2 trials)
• Type 2 diabetes (2 trials)
• Cancer (2 trials)
• Insulin sensitivity (2 trials)
• Duchenne muscular dystrophy (2 trials)
• Endothelial dysfunction (2 trials)

New Horizons in Colorado Research: June's Latest Studies

This month, Colorado welcomes 30 new clinical trials, a slight decrease from the 39 trials that opened in May 2026. Despite the modest dip, these new studies bring significant opportunities, including several notable Phase 3 drug trials from major pharmaceutical companies and large-scale observational studies that could reshape our understanding of health.

Among the most impactful new trials are:

• Kallyope Inc. is sponsoring two crucial Phase 3 trials for migraine treatment. NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," aims to enroll 1,800 participants to assess a new acute migraine treatment. Complementing this, NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," will follow 1,000 participants to evaluate the long-term safety of the same medication.
• AstraZeneca is leading two significant Phase 3 studies for Type 2 Diabetes Mellitus. NCT07662044, "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus," seeks 800 participants. Another AstraZeneca trial, NCT07664553, "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin," will enroll 600 participants. Both trials investigate elecoglipron, a new treatment for T2DM.
• Several large-scale observational studies are also launching, promising to gather vast amounts of data. Longevity Metrics, Inc. is sponsoring NCT07646782, the "Human Observatory Study," a prospective observational study aiming for 1,000,000 participants to build a continuously updating world model for human health. Similarly, NCT07669168, the "Health Ahead Comparative Effectiveness Study," sponsored by William Brandenburg, MD, is a pragmatic interventional platform also targeting 1,000,000 participants to compare changes in preventive health screening.
• NYU Langone Health is leading NCT07656584, "Implementation of Communication Disability Collection and Accommodations in Primary Care Settings," a multi-site study with 126,870 participants to improve documentation and accommodation for patients with communication disabilities in primary care.
• For the Down Syndrome community, RTI International is sponsoring NCT07625579, the "Collaboration for Down Syndrome Progress (CDP)," a long-term study following 1,400 people with Down syndrome of all ages to better understand their health and development.

Conditions and Interventions: A Snapshot of New Research

The 30 new trials opening this month in Colorado cover a diverse range of health conditions, with a notable focus on age-related issues, metabolic health, and cognitive function. The most common conditions addressed by these new studies include:

• Frailty (2 trials)
• Cognitive dysfunction (2 trials)
• Type 2 diabetes mellitus (2 trials)
• Health related quality of life (2 trials)
• Cardiovascular diseases (2 trials)
• Activities of daily living (2 trials)
• Health equity (2 trials)
• Metabolic syndrome (2 trials)
• Aging (2 trials)

In terms of intervention types, drug trials lead the way, accounting for 11 of the new studies. "Other" intervention types, often encompassing observational or registry studies, are also prominent with 9 new trials, alongside device (6), behavioral (5), dietary supplement (2), and procedure (1) research.

Colorado's Research Landscape: Where to Find Trials

Colorado's clinical research landscape remains active, with 1,771 clinical trials currently recruiting across 54 cities and 986 research sites statewide. This month, new research initiatives are concentrated in several key metropolitan areas, ensuring broad access for residents:

• Aurora (14 new trials)
• Boulder (6 new trials)
• Denver (5 new trials)
• Fort Collins (4 new trials)
• Colorado Springs (3 new trials)
• Centennial (2 new trials)
• Steamboat Springs (1 new trial)
• Englewood (1 new trial)
• Lakewood (1 new trial)
• Louisville (1 new trial)

This distribution highlights the strong presence of research hubs in the Denver metro area and along the Front Range, while also showing new opportunities emerging in other parts of the state.

Participation Opportunities: Healthy Volunteers and Diverse Demographics

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 30 new trials launched this month, 7 are actively seeking healthy volunteers. Statewide, a total of 202 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Colorado are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 4 include children as participants, and a substantial 26 include older adults, ensuring that research benefits diverse age groups. One new trial is female-only, and another is male-only, indicating specific research needs. Academic institutions continue to play a vital role in the state's research ecosystem, with the University of Colorado, Denver sponsoring 4 of the new trials. Industry sponsors are also driving significant research efforts, with 17 new trials sponsored by pharmaceutical companies such as AstraZeneca and Kallyope Inc., alongside other organizations like BTL Industries Ltd. and Colorado State University.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Colorado.